miR‑219‑3p regulates the occurrence of hepatic fibrosis by targeting Smad2

  • Authors:
    • Weihua Yin
    • Wei Zhang
    • Yanfang Zhu
    • Huihui Ni
    • Li Gong
    • Maoying Fu
  • View Affiliations

  • Published online on: April 11, 2019     https://doi.org/10.3892/etm.2019.7480
  • Pages: 4635-4642
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Abnormal expression of microRNA (miR)‑219‑3p has been widely identified in different tumors. However, whether miR‑219‑3p is involved in the progression of hepatic fibrosis (HF) has never been explored. The present study showed that compared with healthy controls, the levels of miR‑291‑3p in peripheral blood were decreased in patients with HF. Furthermore, much lower levels of miR‑291‑3p were identified in fibrotic liver tissues compared with that of normal liver tissues. Receiver operating characteristic curve analysis showed that the levels of miR‑291‑3p in peripheral blood may screen patients with HF from healthy controls. Reverse transcription quantitative polymerase chain reaction analysis showed that overexpression of miR‑291‑3p significantly suppressed the mRNA levels of Snai1, vascular endothelial‑specific cadherin (VE‑cadherin), Vimentin, transforming growth factor (TGF)‑β1, and glial fibrillary acidic protein (GFAP). The protein levels of Snai1, VE‑cadherin, Vimentin, TGF‑β1, and GFAP were also decreased in hepatic stellate cells transfected with miR‑291‑3p mimics. Further study indicated that mothers against decapentaplegic homolog 2 (Smad2) was a target gene of miR‑291‑3p. More importantly, silencing of Smad2 could abolish miR‑291‑3p inhibition‑induced TGF‑β1 signaling activation. In summary, reduced peripheral blood miR‑291‑3p may be involved in the progression of HF via targeting Smad2.

References

1 

Xu B, Zhou NM, Cao WT and Li XJ: Evaluation of elastography combined with serological indexes for hepatic fibrosis in patients with chronic hepatitis B. World J Gastroenterol. 24:4272–4280. 2018. View Article : Google Scholar : PubMed/NCBI

2 

Cargnoni A, Farigu S, Cotti Piccinelli E, Bonassi Signoroni P, Romele P, Vanosi G, Toschi I, Cesari V, Barros Sant'Anna L, Magatti M, et al: Effect of human amniotic epithelial cells on pro-fibrogenic resident hepatic cells in a rat model of liver fibrosis. J Cell Mol Med. 22:1202–1213. 2018.PubMed/NCBI

3 

Chen J, Li X, Hu Y, Liu W, Zhou Q, Zhang H, Mu Y and Liu P: Gypenosides ameliorate carbon tetrachloride-induced liver fibrosis by inhibiting the differentiation of hepatic progenitor cells into myofibroblasts. Am J Chin Med. 45:1061–1074. 2017. View Article : Google Scholar : PubMed/NCBI

4 

Chen J, Yu Y, Li S, Liu Y, Zhou S, Cao S, Yin J and Li G: MicroRNA-30a ameliorates hepatic fibrosis by inhibiting Beclin1-mediated autophagy. J Cell Mol Med. 21:3679–3692. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Wells RG: The epithelial-to-mesenchymal transition in liver fibrosis: Here today, gone tomorrow? Hepatology. 51:737–740. 2010.PubMed/NCBI

6 

Fabris L, Brivio S, Cadamuro M and Strazzabosco M: Revisiting epithelial-to-mesenchymal transition in liver fibrosis: Clues for a better understanding of the ‘reactive’ biliary epithelial phenotype. Stem Cells Int. 2016:29537272016. View Article : Google Scholar : PubMed/NCBI

7 

Lim YS, Kim KA, Jung JO, Yoon JH, Suh KS, Kim CY and Lee HS: Modulation of cytokeratin expression during in vitro cultivation of human hepatic stellate cells: Evidence of transdifferentiation from epithelial to mesenchymal phenotype. Histochem Cell Biol. 118:127–136. 2002.PubMed/NCBI

8 

Lim YS, Lee HC and Lee HS: Switch of cadherin expression from E- to N-type during the activation of rat hepatic stellate cells. Histochem Cell Biol. 127:149–160. 2007. View Article : Google Scholar : PubMed/NCBI

9 

Ding YF, Wu ZH, Wei YJ, Shu L and Peng YR: Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine. J Cancer Res Clin Oncol. 143:821–834. 2017. View Article : Google Scholar : PubMed/NCBI

10 

El-Mezayen NS, El-Hadidy WF, El-Refaie WM, Shalaby TI, Khattab MM and El-Khatib AS: Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis. J Control Release. 266:226–237. 2017. View Article : Google Scholar : PubMed/NCBI

11 

Shi J, Zhao J, Zhang X, Cheng Y, Hu J, Li Y, Zhao X, Shang Q, Sun Y, Tu B, et al: Activated hepatic stellate cells impair NK cell anti-fibrosis capacity through a TGF-β-dependent emperipolesis in HBV cirrhotic patients. Sci Rep. 7:445442017. View Article : Google Scholar : PubMed/NCBI

12 

Tang LY, Heller M, Meng Z, Yu LR, Tang Y, Zhou M and Zhang YE: Transforming growth factor-β (TGF-β) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway. J Biol Chem. 292:4302–4312. 2017. View Article : Google Scholar : PubMed/NCBI

13 

Yang JJ, Tao H, Liu LP, Hu W, Deng ZY and Li J: miR-200a controls hepatic stellate cell activation and fibrosis via SIRT1/Notch1 signal pathway. Inflamm Res. 66:341–352. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Zhou G, Lin W, Fang P, Lin X, Zhuge L, Hu Z and Jin L: MiR-10a improves hepatic fibrosis by regulating the TGFβl/Smads signal transduction pathway. Exp Ther Med. 12:1719–1722. 2016. View Article : Google Scholar : PubMed/NCBI

15 

Wang Y, Du J, Niu X, Fu N, Wang R, Zhang Y, Zhao S, Sun D and Nan Y: MiR-130a-3p attenuates activation and induces apoptosis of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2. Cell Death Dis. 8:e27922017. View Article : Google Scholar : PubMed/NCBI

16 

Yu F, Chen B, Fan X, Li G, Dong P and Zheng J: Epigenetically-regulated microRNA-9-5p suppresses the activation of hepatic stellate cells via TGFBR1 and TGFBR2. Cell Physiol Biochem. 43:2242–2252. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Long J, Menggen Q, Wuren Q, Shi Q and Pi X: MiR-219-5p inhibits the growth and metastasis of malignant melanoma by targeting BCL-2. Biomed Res Int. 2017:90325022017. View Article : Google Scholar : PubMed/NCBI

18 

Wang Q, Zhu L, Jiang Y, Xu J, Wang F and He Z: miR-219-5p suppresses the proliferation and invasion of colorectal cancer cells by targeting calcyphosin. Oncol Lett. 13:1319–1324. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Guo J, Li M, Meng X, Sui J, Dou L, Tang W, Huang X, Man Y, Wang S and Li J: MiR-291b-3p induces apoptosis in liver cell line NCTC1469 by reducing the level of RNA-binding protein HuR. Cell Physiol Biochem. 33:810–822. 2014. View Article : Google Scholar : PubMed/NCBI

20 

Meng X, Guo J, Fang W, Dou L, Li M, Huang X, Zhou S, Man Y, Tang W, Yu L and Li J: Liver microRNA-291b-3p promotes hepatic lipogenesis through negative regulation of adenosine 5′-monophosphate (AMP)-activated protein kinase α1. J Biol Chem. 291:10625–10634. 2016. View Article : Google Scholar : PubMed/NCBI

21 

Guo J, Dou L, Meng X, Chen Z, Yang W, Fang W, Yang C, Huang X, Tang W, Yang J and Li J: Hepatic MiR-291b-3p mediated glucose metabolism by directly targeting p65 to upregulate PTEN expression. Sci Rep. 7:398992017. View Article : Google Scholar : PubMed/NCBI

22 

Weiskirchen R and Gressner AM: Isolation and culture of hepatic stellate cells. Methods Mol Med. 117:99–113. 2005.PubMed/NCBI

23 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

24 

Carotti S, Morini S, Corradini SG, Burza MA, Molinaro A, Carpino G, Merli M, De Santis A, Muda AO, Rossi M, et al: Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl. 14:806–814. 2008. View Article : Google Scholar : PubMed/NCBI

25 

Bai X, Saab AS, Huang W, Hoberg IK, Kirchhoff F and Scheller A: Genetic background affects human glial fibrillary acidic protein promoter activity. PLoS One. 8:e668732013. View Article : Google Scholar : PubMed/NCBI

26 

Romão LF, Sousa Vde O, Neto VM and Gomes FC: Glutamate activates GFAP gene promoter from cultured astrocytes through TGF-beta1 pathways. J Neurochem. 106:746–756. 2008. View Article : Google Scholar : PubMed/NCBI

27 

Zheng JY, Sun J, Ji CM, Shen L, Chen ZJ, Xie P, Sun YZ and Yu RT: Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer's disease (APP/PS1) mice by inhibiting TGF-β/Smad2/STAT3 signaling. Neurobiol Aging. 54:112–132. 2017. View Article : Google Scholar : PubMed/NCBI

28 

Hassan S, Syed S and Kehar SI: Glial fibrillary acidic protein (GFAP) as a mesenchymal marker of early hepatic stellate cells activation in liver fibrosis in chronic hepatitis C infection. Pak J Med Sci. 30:1027–1032. 2014.PubMed/NCBI

29 

Hu Z, Qin F, Gao S, Zhen Y, Huang D and Dong L: Paeoniflorin exerts protective effect on radiation-induced hepatic fibrosis in rats via TGF-β1/Smads signaling pathway. Am J Transl Res. 10:1012–1021. 2018.PubMed/NCBI

30 

Jiang Y, Wang C, Li YY, Wang XC, An JD, Wang YJ and Wang XJ: Mistletoe alkaloid fractions alleviates carbon tetrachloride-induced liver fibrosis through inhibition of hepatic stellate cell activation via TGF-β/Smad interference. J Ethnopharmacol 158 Pt A. 230–238. 2014. View Article : Google Scholar

31 

Wang J, Chu ES, Chen HY, Man K, Go MY, Huang XR, Lan HY, Sung JJ and Yu J: microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget. 6:7325–7338. 2015.PubMed/NCBI

32 

Lamb CL, Cholico GN, Pu X, Hagler GD, Cornell KA and Mitchell KA: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) increases necroinflammation and hepatic stellate cell activation but does not exacerbate experimental liver fibrosis in mice. Toxicol Appl Pharmacol. 311:42–51. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Liu YW, Chiu YT, Fu SL and Huang YT: Osthole ameliorates hepatic fibrosis and inhibits hepatic stellate cell activation. J Biomed Sci. 22:632015. View Article : Google Scholar : PubMed/NCBI

34 

Nunez Lopez O, Bohanon FJ, Wang X, Ye N, Corsello T, Rojas-Khalil Y, Chen H, Chen H, Zhou J and Radhakrishnan RS: STAT3 inhibition suppresses hepatic stellate cell fibrogenesis: HJC0123, a potential therapeutic agent for liver fibrosis. RSC Adv. 6:100652–100663. 2016. View Article : Google Scholar : PubMed/NCBI

35 

Perumal N, Perumal M, Halagowder D and Sivasithamparam N: Morin attenuates diethylnitrosamine-induced rat liver fibrosis and hepatic stellate cell activation by co-ordinated regulation of Hippo/Yap and TGF-β1/Smad signaling. Biochimie. 140:10–19. 2017. View Article : Google Scholar : PubMed/NCBI

36 

Zhang Z, Zha Y, Hu W, Huang Z, Gao Z, Zang Y, Chen J, Dong L and Zhang J: The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. J Biol Chem. 288:37082–37093. 2013. View Article : Google Scholar : PubMed/NCBI

37 

Zhou L, Liu S, Han M, Ma Y, Feng S, Zhao J, Lu H, Yuan X and Cheng J: miR-185 inhibits fibrogenic activation of hepatic stellate cells and prevents liver fibrosis. Mol Ther Nucleic Acids. 10:91–102. 2018. View Article : Google Scholar : PubMed/NCBI

38 

Roderburg C, Luedde M, Vargas Cardenas D, Vucur M, Mollnow T, Zimmermann HW, Koch A, Hellerbrand C, Weiskirchen R, Frey N, et al: miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. J Hepatol. 58:736–742. 2013. View Article : Google Scholar : PubMed/NCBI

39 

Xiao YH, Liu DW and Li Q: Effects of drug serum of anti-fibrosis I herbal compound on calcium in hepatic stellate cell and its molecular mechanism. World J Gastroenterol. 11:1515–1520. 2005. View Article : Google Scholar : PubMed/NCBI

40 

Liu LX, Zhang HY, Zhang QQ and Guo XH: Effects of insulin-like growth factor binding protein-related protein 1 in mice with hepatic fibrosis induced by thioacetamide. Chin Med J (Engl). 123:2521–2526. 2010.PubMed/NCBI

41 

Zakaria S, Youssef M, Moussa M, Akl M, El-Ahwany E, El-Raziky M, Mostafa O, Helmy AH and El-Hindawi A: Value of α-smooth muscle actin and glial fibrillary acidic protein in predicting early hepatic fibrosis in chronic hepatitis C virus infection. Arch Med Sci. 6:356–365. 2010. View Article : Google Scholar : PubMed/NCBI

42 

Castera L: Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol. 25:291–303. 2011. View Article : Google Scholar : PubMed/NCBI

43 

Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD and Grigorescu M: Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon. 12:177–184. 2012. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yin, W., Zhang, W., Zhu, Y., Ni, H., Gong, L., & Fu, M. (2019). miR‑219‑3p regulates the occurrence of hepatic fibrosis by targeting Smad2. Experimental and Therapeutic Medicine, 17, 4635-4642. https://doi.org/10.3892/etm.2019.7480
MLA
Yin, W., Zhang, W., Zhu, Y., Ni, H., Gong, L., Fu, M."miR‑219‑3p regulates the occurrence of hepatic fibrosis by targeting Smad2". Experimental and Therapeutic Medicine 17.6 (2019): 4635-4642.
Chicago
Yin, W., Zhang, W., Zhu, Y., Ni, H., Gong, L., Fu, M."miR‑219‑3p regulates the occurrence of hepatic fibrosis by targeting Smad2". Experimental and Therapeutic Medicine 17, no. 6 (2019): 4635-4642. https://doi.org/10.3892/etm.2019.7480